Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):1–6. doi:10.3322/caac.21551.
   Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
   Google Scholar
• Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. doi:10.1136/gutjnl-2015-310912.
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med. 2015;66(1):83–95. doi:10.1146/annurev-med-051513-102539.
   PubMedGoogle Scholar
• Bajaj J, Diaz E, Reya T. Stem cells in cancer initiation and progression. J Cell Biol. 2020 Jan 6;219(1). doi:10.1083/jcb.201911053.
   PubMed Web of Science ®Google Scholar
• Yadav AK, Desai NS. Cancer stem cells: acquisition, characteristics, therapeutic implications, targeting strategies and future prospects. Stem Cell Rev Reports. 2019 Jun 15;15(3):331–355. doi:10.1007/s12015-019-09887-2.
   PubMed Web of Science ®Google Scholar
• Atashzar MR, Baharlou R, Karami J, Abdollahi H, Rezaei R, Pourramezan F, Zoljalali Moghaddam SH. Cancer stem cells: A review from origin to therapeutic implications. J Cell Physiol. 2020 Feb;235(2):790–803. doi:10.1002/jcp.29044.
   PubMed Web of Science ®Google Scholar
• Wong AL, Bellot GL, Hirpara JL, Pervaiz S. Understanding the cancer stem cell phenotype: A step forward in the therapeutic management of cancer. Biochem Pharmacol. 2019 Apr 1;162:79–88.
   Web of Science ®Google Scholar
• Vijayakumar G, Narwal A, Kamboj M, Sen R. Association of SOX2, OCT4 and WNT5A expression in oral epithelial dysplasia and oral squamous cell carcinoma: an immunohistochemical study. Head Neck Pathol. 2020 Jan;4:1–9.
   Google Scholar
• Panayiotou T, Michael S, Zaravinos A, Demirag E, Achilleos C, Strati K. Human papillomavirus E7 binds Oct4 and regulates its activity in HPV-associated cervical cancers. PLoS Pathog. 2020 Apr 16;16(4):e1008468. doi:10.1371/journal.ppat.1008468.
   PubMed Web of Science ®Google Scholar
• Mohiuddin IS, Wei SJ, Kang MH. Role of OCT4 in cancer stem-like cells and chemotherapy resistance. Biochimica Biophysica Acta Mol Basis Dis. 2020 Apr 1;1866(4):165432.
   Web of Science ®Google Scholar
• Jeter CR, Yang T, Wang J, Chao HP, Tang DG. Concise review: NANOG in cancer stem cells and tumor development: an update and outstanding questions. Stem Cells. 2015;33(8):2381–2390. doi:10.1002/stem.2007.
   PubMed Web of Science ®Google Scholar
• Gong S, Li Q, Jeter CR, Fan Q, Tang DG, Liu B. Regulation of NANOG in cancer cells. Mol Carcinog. 2015;54(9):679–687. doi:10.1002/mc.22340.
   PubMed Web of Science ®Google Scholar
• Mahalaxmi I, Devi SM, Kaavya J, Arul S, Balachandar V, Santhy KS. New insight into NANOG: A novel therapeutic target for ovarian cancer (OC). Eur J Pharmacol. 2019 Jun 5;852:51–57.
   Web of Science ®Google Scholar
• Dehghan Harati M, Rodemann HP, Toulany M. Nanog signaling mediates radioresistance in ALDH-positive breast cancer cells. Int J Mol Sci. 2019 Jan;20(5):1151. doi:10.3390/ijms20051151.
   PubMed Web of Science ®Google Scholar
• de Vicente JC, Rodríguez-Santamarta T, Rodrigo JP, Allonca E, Vallina A, Singhania A. Donate-Pérez del Molino P, García-Pedrero JM. The Emerging Role of NANOG as an Early Cancer Risk Biomarker in Patients with Oral Potentially Malignant Disorders. J Clin Med. 2019 Sep;8(9):1376.
   Web of Science ®Google Scholar
• Ye T, Li J, Sun Z, Liu Y, Kong L, Zhou S, Tang J, Wang J, Xing HR. Nr5a2 promotes cancer stem cell properties and tumorigenesis in nonsmall cell lung cancer by regulating Nanog. Cancer Med. 2019 Mar;8(3):1232–1245. doi:10.1002/cam4.1992.
   PubMed Web of Science ®Google Scholar
• Grubelnik G, Boštjančič E, Pavlič A, Kos M, Zidar N. NANOG expression in human development and cancerogenesis. Exp Biol Med. 2020 Mar;245(5):456–464. doi:10.1177/1535370220905560.
   PubMed Web of Science ®Google Scholar
• Cao Y, Deng S, Yan L, Gu J, Li J, Wu K, Cai K. Perineural invasion is associated with poor prognosis of colorectal cancer: a retrospective cohort study. Int J Colorectal Dis. 2020 Mar;16:1–9.
   Google Scholar
• Yang Y, Huang X, Sun J, Gao P, Song Y, Chen X, Zhao J, Wang Z. Prognostic value of perineural invasion in colorectal cancer: a meta-analysis. J Gastrointestinal Surg. 2015 Jun 1;19(6):1113–1122. doi:10.1007/s11605-015-2761-z.
   PubMed Web of Science ®Google Scholar
• Sadeghi A, Roudi R, Mirzaei A, Zare Mirzaei A, Madjd Z, Abolhasani M. CD44 epithelial isoform inversely associates with invasive characteristics of colorectal cancer. Biomark Med. 2019;13(6):419–426. doi:10.2217/bmm-2018-0337.
   PubMed Web of Science ®Google Scholar
• Korourian A, Roudi R, Shariftabrizi A, Kalantari E, Sotoodeh K, Madjd Z. Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness. Clin Exp Med. 2017;17(4):505–517. doi:10.1007/s10238-016-0443-0.
   PubMed Web of Science ®Google Scholar
• Kalantari E, Asadi Lari MH, Roudi R, Korourian A, Madjd Z. Lgr5High/DCLK1High phenotype is more common in early stage and intestinal subtypes of gastric carcinomas. Cancer Biomarkers. 2017;20(4):563–573. doi:10.3233/CBM-170383.
   PubMed Web of Science ®Google Scholar
• Roudi R, Korourian A, Shariftabrizi A, Madjd Z. Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes. Cancer Invest. 2015;33(7):294–302. doi:10.3109/07357907.2015.1034869.
   PubMed Web of Science ®Google Scholar
• Mansoori M, Roudi R, Abbasi A, Abolhasani M, Abdi Rad I, Shariftabrizi A, Madjd Z. High GD2 expression defines breast cancer cells with enhanced invasiveness. Exp Mol Pathol. 2019;109:25–35. doi:10.1016/j.yexmp.2019.05.001.
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ, Watanabe T. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065. doi:10.1038/nrdp.2015.65.
   PubMed Web of Science ®Google Scholar
• Hirata A, Hatano Y, Niwa M, Hara A, Tomita H. Heterogeneity of colon cancer stem cells. Adv Exp Med Biol. 2019;1139:115–126.
   PubMed Web of Science ®Google Scholar
• Zhang J, Espinoza LA, Kinders RJ, Lawrence SM, Pfister TD, Zhou M, Veenstra TD, Thorgeirsson SS, Jessup JM. NANOG modulates stemness in human colorectal cancer. Oncogene. 2013;32(37):4397–4405. doi:10.1038/onc.2012.461.
   PubMed Web of Science ®Google Scholar
• Gazouli M, Roubelakis MG, Theodoropoulos GE, Papailiou J, Vaiopoulou A, Pappa KI, Nikiteas N, Anagnou NP. OCT4 spliced variant OCT4B1 is expressed in human colorectal cancer. Mol Carcinog. 2012;51(2):165–173. doi:10.1002/mc.20773.
   PubMed Web of Science ®Google Scholar
• Tiwari D, Ray Das C, Sultana R, Kakoti S, Aasif Khan M, Dongre A, Husain SA, Bose PD, Bose S. Impact of modulation of telomerase and cancer stem-cell marker OCT4 axis in cervical cancer pathogenesis with underlying HPV16 infection. 2020 Apr;121(4):2782–279.
   Google Scholar
• Talebi A, Kianersi K, Beiraghdar M. Comparison of gene expression of SOX2 and OCT4 in normal tissue, polyps, and colon adenocarcinoma using immunohistochemical staining. Adv Biomed Res. 2015;4:234.
   PubMedGoogle Scholar
• Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, Miki C, Kusunoki M. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009 Dec 1;16(12):3488–3498. doi:10.1245/s10434-009-0617-z.
   PubMed Web of Science ®Google Scholar
• Matsuoka J, Yashiro M, Sakurai K, Kubo N, Tanaka H, Muguruma K, Sawada T, Ohira M, Hirakawa K. Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Sur Res. 2012;174(1):130–135. doi:10.1016/j.jss.2010.11.903.
   PubMed Web of Science ®Google Scholar
• Amini AQ, Samo KA, Memon AS. Colorectal cancer in younger population: our experience. J Pak Med Assoc. 2013;63:1275–1277.
   PubMed Web of Science ®Google Scholar
• Trivanovic D, Krstic J, Jaukovic A, Bugarski D, Santibanez JF. Mesenchymal stromal cell engagement in cancer cell epithelial to mesenchymal transition. Developmen Dynam. 2018;247(3):359–367.
   Google Scholar
• Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. doi:10.1038/s41580-018-0080-4.
   PubMed Web of Science ®Google Scholar
• Fischedick G, Wu G, Adachi K, Arauzo-Bravo MJ, Greber B, Radstaak M, Köhler G, Tapia N, Iacone R, Anastassiadis K, et al. Nanog induces hyperplasia without initiating tumors. Stem Cell Res. 2014;13(2):300–315. doi:10.1016/j.scr.2014.08.001.
   PubMed Web of Science ®Google Scholar
• Vaz MA, Martinez JC, Devesa JM, Trill JD, Abraira V, Riquelme A, Carrato A. Prognostic value of stem cell quantification in stage II colon cancer. PLoS One. 2014;9(2):e88480. doi:10.1371/journal.pone.0088480.
   PubMed Web of Science ®Google Scholar
• Meng HM, Zheng P, Wang XY, Liu C, Sui HM, Wu SJ, Zhou J, Ding Y-Q, Li J. Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther. 2010;9(4):295–302. doi:10.4161/cbt.9.4.10666.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Tanaka K, Okita Y, Araki T, Saigusa S, Toiyama Y, Yokoe T, Yoshiyama S, Kawamoto A, Inoue Y, et al. CD133, OCT4, and NANOG in ulcerative colitis-associated colorectal cancer. Oncol Lett. 2011;2(6):1065–1071. doi:10.3892/ol.2011.415.
   PubMed Web of Science ®Google Scholar
• Xu F, Dai C, Zhang R, Zhao Y, Peng S, Jia C. Nanog: a potential biomarker for liver metastasis of colorectal cancer. Dig Dis Sci. 2012;57(9):2340–2346. doi:10.1007/s10620-012-2182-8.
   PubMed Web of Science ®Google Scholar
• Saiki Y, Ishimaru S, Mimori K, Takatsuno Y, Nagahara M, Ishii H, Yamada K, Mori M. Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol. 2009;16(9):2638–2644. doi:10.1245/s10434-009-0567-5.
   PubMed Web of Science ®Google Scholar
• Liang C, Zhao T, Ge H, Xu Y, Ren S, Yue C, Li G, Wu J. The clinicopathological and prognostic value of Nanog in human gastrointestinal luminal cancer: A meta-analysis. Int J Surg (London, England). 2018;53:193–200. doi:10.1016/j.ijsu.2018.03.050.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh KM, Safary A, Barar J, Ajoolabady A, Somi MH, Omidi Y. Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer. Cellular Mol Life Sci. 2020 Mar;77(6):997–1019.
   Web of Science ®Google Scholar
• Khiavi MA, Safary A, Somi MH. Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates. BioImpacts. 2019;9(3):123. doi:10.15171/bi.2019.16.
   PubMed Web of Science ®Google Scholar
• Safary A, Moniri R, Hamzeh-Mivehroud M, Dastmalchi S. Highly efficient novel recombinant L-asparaginase with no glutaminase activity from a new halo-thermotolerant Bacillus strain. BioImpacts. 2019;9(1):15. doi:10.15171/bi.2019.03.
   PubMed Web of Science ®Google Scholar